Eurofins Scientific Full Year 2024 Earnings: EPS Misses Expectations

Eurofins Scientific (EPA:ERF) Full Year 2024 Results

Key Financial Results

• Revenue: €6.95b (up 6.7% from FY 2023).
• Net income: €356.3m (up 39% from FY 2023).
• Profit margin: 5.1% (up from 3.9% in FY 2023).
• EPS: €1.87 (up from €1.33 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eurofins Scientific EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%.

The primary driver behind last 12 months revenue was the Europe segment contributing a total revenue of €3.60b (52% of total revenue). Notably, cost of sales worth €5.39b amounted to 78% of total revenue thereby underscoring the impact on earnings. The most substantial expense, totaling €541.5m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how ERF's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.

Performance of the market in France.

The company's shares are down 1.0% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Eurofins Scientific you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.